Alector to Present at Upcoming Virtual Healthcare Conferences

Rhea-AI Summary

Alector, a clinical-stage biotechnology company pioneering immuno-neurology, has announced participation in several upcoming virtual investor conferences. Key events include:

• Citi’s 16th Annual Biopharma Virtual Conference: Sept 8 at 11:35 a.m. ET and Sept 9 at 1:25 p.m. ET.
• Wells Fargo Virtual Healthcare Conference: Sept 10 at 2:00 p.m. ET.
• Morgan Stanley 19th Annual Global Healthcare Conference: Sept 13 at 11:45 a.m. ET.

Webcasts will be available on the Alector website, with replays for 30 days.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming virtual investor conferences:

• Citi’s 16^th Annual Biopharma Virtual Conference
  • Wednesday, September 8, 2021 at 11:35 a.m. ET, What’s Next for Neurodegenerative Diseases Panel
  • Thursday, September 9, 2021 at 1:25 p.m. ET, Fireside Chat
• The 2021 Wells Fargo Virtual Healthcare Conference
  • Friday, September 10, 2021 at 2:00 p.m. ET, Corporate Presentation
• The Morgan Stanley 19^th Annual Global Healthcare Conference
  • Monday, September 13, 2021 at 11:45 a.m. ET, Fireside Chat
    

Live webcasts of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.  Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts
Michelle Corral
VP, Communications and Investor Relations
650-808-7016
michelle.corral@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry/Eric Kasper
Argot Partners
212.600.1902
alector@argotpartners.com

 

FAQ

What are the dates of Alector's virtual investor conferences?

Alector's virtual investor conferences are scheduled for September 8, 9, 10, and 13, 2021.

How can I access the webcasts for Alector's conferences?

Webcasts for Alector's conferences can be accessed on the 'Events & Presentations' page of Alector's Investors section.

What is the focus of Alector's research?

Alector focuses on immuno-neurology, aiming to treat neurodegenerative diseases by targeting immune dysfunction.

Where is Alector's headquarters located?

Alector is headquartered in South San Francisco, California.

What is the stock symbol for Alector?

Alector is traded under the stock symbol ALEC on Nasdaq.